Form 4: Allurion Technologies COO Receives 306,749 Restricted Stock Units
SEC Form 4 Filing
Allurion Technologies' Chief Operating Officer, Ojas Buch, was granted 306,749 restricted stock units (RSUs) under the company's 2023 Stock Option and Incentive Plan.
Summary
- Ojas Buch, the Chief Operating Officer of Allurion Technologies, Inc., received 306,749 restricted stock units (RSUs).
- These RSUs were granted under the company's 2023 Stock Option and Incentive Plan.
- Each RSU represents the right to receive one share of Allurion's common stock.
- The RSUs will vest over a two-year period, with 50% vesting on November 8, 2025, and the remaining 50% vesting on November 8, 2026.
- Vesting is contingent upon Mr. Buch's continued service with the company on each vesting date.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.
Positives
- The grant of RSUs to the COO aligns his interests with the long-term success of the company.
- The vesting schedule encourages continued service and commitment from the COO.
Risks
- The value of the RSUs is dependent on the future performance of Allurion's stock price.
- If Mr. Buch leaves the company before the vesting dates, he will forfeit the unvested RSUs.
Industry Context
The granting of stock-based compensation is a common practice in the technology and healthcare industries to incentivize key executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock-based compensation, such as RSUs, is a standard practice for companies like Allurion to attract and retain top talent.
- Companies such as InMode, Silk Road Medical, and Inspire Medical Systems also use similar equity-based compensation plans for their executives.
- The vesting schedule of two years is also typical for RSU grants in the industry.
Stakeholder Impact
- The RSU grant may have a minor positive impact on shareholder sentiment as it aligns management's interests with the company's long-term success.
- The grant does not have a direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 11/08/2024 | Date of the RSU grant to Ojas Buch. |
| 11/08/2025 | First vesting date for 50% of the RSUs. |
| 11/08/2026 | Second vesting date for the remaining 50% of the RSUs. |
| 11/12/2024 | Date the Form 4 was signed. |
Keywords
Restricted Stock Units, RSU, Stock Options, Incentive Plan, Equity Compensation, Allurion Technologies, Ojas Buch, Chief Operating Officer, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.